1Soubeyran I, Quénel N, Mauriac L, et al. Variation of hormonal receptor, pS2, C-erbB2 and GST-π contents in breast carcinoma under tamoxifen: a study of 74 cases. Br J Cancer, 1996,73(3):735-739.
2Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res, 1994,54(6):4855-4878.
3Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst, 1993,85(4):200-205.
4Dunning AM, Healey CS, Pharoah PDP, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 1999, 8(10):843-854.
5Gudmundsdottir K, Tryggvadottir L, Eyfjord JE. GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene. Cancer Epidemiol Biomarkers Prev, 2001,10(11):1169-1173.
6Gilbert BL, Elwood LJ, Merino M, et al. A pilot study of Pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol, 1993,11(1):49-58.
